The U.S. Food and Drug Administration today approved Allergan PLC’s Juvéderm Ultra XC for lip augmentation in adults who are at least 21 years old.
Allergan’s facial aesthetic and eye drug hubs are located in Irvine. Allergan, once known as Allergan Inc., was based there until it was acquired earlier this year for $72 billion by Dublin, Ireland-based Actavis PLC. The combined company took on the Allergan name.
Juvéderm was first cleared by the FDA in 2006 and is used for several lower-face filling procedures, including age-related volume loss.
Shares of Allergan rose 2% in midday trading to a market value of $109 billion.
